InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,573.20
(
-2.14%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.63
(
0.24%
)
Bitcoin
64,373.91
(
1.36%
)
Post# of 363438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jimmybob

Send PM Follow Ignore
Followers 1879
Posts 137421
Boards Moderated 5
Alias Born 01/03/2007

jimmybob

Re: jimmybob post# 316541

Wednesday, 08/16/2017 7:39:11 AM

Wednesday, August 16, 2017 7:39:11 AM

Post# of 363438
Biogen upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Terence Flynn added Biogen to the Conviction Buy List and maintained a $338 price target saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. He expects Phase 3 data in Q4 2019/Q1 2020 saying it could be the first disease modifying drugs on the market with a peak sales estimated at $12B. Further, the analyst views MS competition concerns as overdone and said the balance sheet is relatively under-levered

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up